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Abstract: 
Water-in-oil (W/O) Lipiodol emulsions remain the preferable choice for local delivery of 
chemotherapy in the treatment of hepatocellular carcinoma. However, their low stability 
severely hampers their efficiency. Here, remarkably stable W/O Lipiodol emulsion stabilized 
by biodegradable particles was developed thanks to Pickering technology. The addition of 
poly(lactide-co-glycolide) nanoparticles (NPs) into the aqueous-phase of the formulation led 
to W/O Pickering emulsion by a simple emulsification process through two connected 
syringes. Influence of nanoparticles concentration and water/oil ratio on emulsion stability 
and droplet size were studied. All formulated Pickering emulsions were W/O type, stable for 
at least one month and water droplets size could be tuned by controlling nanoparticle 
concentration from 24 µm at 25 mg/mL to 69 µm at 5 mg/mL. The potential of these 
emulsions to efficiently encapsulate chemotherapy was studied through the internalization of 
doxorubicin (DOX) into the aqueous phase with a water/oil ratio of 1/3 as recommended by 
the medical community. Loaded-doxorubicin was released from conventional emulsion within 
a few hours whereas doxorubicin from stable Pickering emulsion took up to 10 days to be 
completely released. In addition, in vitro cell viability evaluations performed on the 
components of the emulsion and the Pickering emulsion have shown no significant toxicity up 
to relatively high concentrations of NPs (3 mg/mL) on two different cell lines: HUVEC and 
HepG2. 
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1. Introduction 
Emulsions using ethiodized oil (Lipiodol) are currently used for the local delivery of 
chemotherapy to unresectable Hepatocellular Carcinoma (HCC) during liver Trans-Arterial 
Chemo-Embolization (TACE). This is a widely performed and recognized procedure owing to 
its selectivity for the tumor tissue over prolonged periods [1]. The advantage of using a 
Lipiodol emulsion for the treatment of HCC is threefold: 1) an embolic effect, enhanced in the 
case of a water-in-oil (W/O) emulsion [2], 2) the release of an anticancer drug dissolved in the 
water emulsion droplets (the emulsion acts as a transient reservoir, allowing a slow release of 
the chemotherapy into the tumors’ supply and a prolonged exposure of the tumor cells while 
minimizing systemic exposures[1]), and 3) the radio-opacity of the Lipiodol, which ensures 
easy monitoring of the injection into the patient under X-ray guidance. 
A major challenge in the formulation of W/O Lipiodol emulsions consists in the improvement 
of their stability. Today, their use has been limited since rapidly, the two phases of the 
emulsion separate in vitro as well as in vivo leading to the clearance of almost all the water 
soluble chemotherapeutic agent from the tumor and to high systemic exposure [2,3]. Several 
approaches have been attempted to improve stability. These include the use of contrast agent 
for preparation of chemotherapy aqueous phase, and/or the modification of technical 
parameters (water-in-oil vs oil-in-water, different ratios of lipiodol and drug, various 
emulsification techniques) [4–7]. However, no real worldwide recommendation was adopted 
and Lipiodol emulsions remain unstable systems. A solution, among others, is the use of 
stabilizers during formulation for long term stability. Emulsifiers are able to promote 
emulsification by decreasing the interfacial tension between the phases and to stabilize the 
interface between the droplets and the external phase [3,8]. Their adsorption at the interface 
leads to the formation of a protective film, which prevents droplets coalescence and phase 
separation, thus favoring emulsion stabilization. Although synthetic surfactants have been so 
far used to stabilize pharmaceutical emulsions, this kind of emulsifiers raises directly or 
indirectly toxicity issues [9,10]. In particular, for parenteral administration, cytotoxicity and 
haemolysis have been observed for most of them [11,12]. 
The use of solid particles in the formulation of an emulsion allows to lower, or even to avoid, 
the use of synthetic surfactants, and very stable interfaces are obtained. Such emulsions 
stabilized by solid particles are called Pickering emulsions [13,14]. Compared with classical 
emulsions stabilized by surfactants, Pickering emulsions display outstanding stability, lower 
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toxicity and have the ability to stabilize emulsions with large droplet size, so that a classical 
emulsion can be substituted by a Pickering emulsion in most applications [15]. Despite their 
potential, Pickering emulsions have certain characteristics less favourable for biomedical 
applications, one of which is the nature of the stabilizing particles. Indeed, particles are 
foreign bodies which may provoke a prolonged inflammatory response with potential 
deleterious effects. Due to their small size, particles develop a large surface of activation. 
Since particles are intended to be injected in the organism, they have to be biocompatible, 
biodegradable and their degradation products have to be rapidly eliminated to avoid any 
accumulation in the body. Recently, Whitby et al have reported the use of biodegradable 
particles as stabilizers rather than usual organic or inorganic particles such as silica, calcium 
carbonate, polystyrene [16]. These biodegradable particle made of poly(lactic-co-glycolic 
acid) (PLGA) offer the advantage of being biocompatible and rapidly eliminated from the 
body preventing potential inflammatory reaction by their accumulation [17–19]. However, in 
this study, non-pharmaceutical oils were tested and the resulting emulsions were therefore not 
biocompatible. 
In this context, biodegradable Pickering emulsions could be considered as an attractive 
approach to stabilize Lipiodol emulsion. Lipiodol has already a marketing authorization as an 
agent for chemoembolization of HCC and is commonly injected into hepatic arteries for its 
ability to target liver tumors. Its combination with biodegradable and biocompatible PLGA 
particles will render this Lipiodol Pickering emulsion fully acceptable for injection. 
Nevertheless, the well-known established parameters for conventional lipiodol emulsions 
have to be maintained: (i) one needs to obtain a W/O emulsion for higher tumor selectivity, 
(ii) droplet sizes should be from 20 to 40 µm since vessels diameter close to the tumor is 
around 40-60 µm, (iii) a high viscosity is needed to increase its tumor retention, and 
ultimately (iv) a high loadable capacity in chemotherapeutic agent is required. Moreover, to 
be transposable in clinic, emulsification has to be obtained by repetitive pumping of 2 
syringes (1 of chemotherapy and 1 of Lipiodol) through a 3-ways stopcock [20]. 
We report herein the feasibility of formulating W/O Pickering emulsion for TACE with 
biodegradable nanoparticles of PLGA. The impact of nanoparticle concentration and the 
water/oil ratio on the above mentioned parameters was studied by following the stability and 
the droplet size of the emulsion. The potential of this new system to load and release 
doxorubicin without affecting the global stability was then evaluated in-vitro. Finally, 
biocompatibility of each component and the whole emulsion was assessed on two cell lines: 
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HUVEC human endothelial cells and HepG2, human hepatocyte carcinomas, representative 
of the target tissues. 
2. Materials and methods 
2.1. Materials 
Poly(lactide-co-glycolide) (PLGA, 75:25) was provided by Evonik (Germany). Poly(vinyl 
alcohol) (PVA, molecular weight 30,000–70,000 g/mol, 87–90% hydrolyzed), and D-
trehalose (from saccharomyces cerevisiae, ≥ 99%) were obtained from Sigma Aldrich 
(France). Iron oxide nanoparticles suspension (Fe3O4 with oleic acid coating, ~5 nm, 25 
mg/mL in chloroform) was provided by Ocean NanoTech (USA). Acetone was purchased 
from Carlo Erba (Milan, Italy). Distilled water was obtained by purification, using a water 
system ultrapure MilliQ Direct Type 1 (Millipore, resistivity of 18.2 MΩ.cm, France). 
Lipiodol® was purchased from Guerbet (France). Finally, doxorubicin hydrochloride 
(Adriblastin, 50 mg, lyophilized form) was provided by Pfizer (USA). 
2.2.  Nanoparticles formulation 
PLGA nanoparticules (NPs) were prepared using a nanoprecipitation technique. 100 mg of 
PLGA were dissolved in 10 mL of acetone. The PLGA solution was slowly added through a 
syringe pump into a 30 mL solution of PVA at 0.5% w/w. This mixture was stirred for 10 
hours at room temperature. Then, two successive ultracentrifugations were performed to 
eliminate free PVA, the pellets were collected and suspended into a solution of trehalose at 
5% w/w. For ease of handling, the NPs suspension was freeze-dried and stored at -20°C. The 
main characteristics of the NPs are summarized Table 1. 
For confocal microscopy to clearly distinguish signals from doxorubicin and NPs, iron oxide 
containing PLGA NPs were prepared by a emulsion-evaporation process as described by 
Okassa et al [21]. 
2.3. Nanoparticles characterization 
Size distribution and Zeta potential: The size distribution and zeta potential of NPs were 
measured with a Zetasizer (Nano ZS 90, Malvern Instruments, France, 633 nm He-Ne laser, 
Smoluchowski equation) operating at 25 °C with a 173° scattering angle. The NPs suspension 
was diluted in MilliQ water for size distribution measurements and in a 1 mM NaCl aqueous 
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solution for zeta potential measurements. Three measurements were performed for each NPs 
formulation (Table 1). 
Transmission Electron Microscopy: Transmission Electron Microscopy (TEM) was 
performed at I2BC (Gif-sur-Yvette, France) using a JEOL JEM-1400 operating at 80 kV. 5 
µL of purified suspensions of NPs (0.5 mg/mL) were deposited for 1 min on glow-discharged 
copper grids covered with formvar-carbon film. Samples were then stained two times using 
uranyl acetate for 10 s. The excess solution was blotted off using a filter paper. Images were 
acquired using an Orius camera (Gatan Inc, USA). 
Wetting properties: Wetting properties of NPs were evaluated with contact angle 
measurements. A NP layer was formed on a mica surface by deposition of a 45 µL drop of NP 
suspension in water at 25 mg/mL which was dried during 15 h at 25 °C. Droplets of saline or 
of Lipiodol (volume: 5 µL) are carefully deposited on the NP layer, and the contact angle was 
measured at t = 0 at 20 °C with the sessile drop technique by a pendant drop tensiometer 
(Tracker, Teclis, France). Measurements were repeated 10 times (Table 1). 
 
Diameter (nm) PdI Zeta potential (mV) Contact angle (°) 
   Lipiodol saline 
170 ± 5 0.08 - 4 ± 1 35 ± 5 61 ± 12 
Table 1. Physico-chemical properties of the PLGA nanoparticles (NPs). 
2.4. Emulsion formulation 
For the entire study, the aqueous-phase used was a suspension of PLGA NPs in physiological 
saline and the oil phase was Lipiodol (Guerbet, France®). For all formulations, the Lipiodol 
volume was fixed at 3 mL.  
Four different NPs concentrations were tested: 5, 10, 15 and 25 mg/mL at a 1/3 water/oil ratio 
(v/v). At a fixed NPs concentration of 15 mg/mL, 4 different water/oil ratios (v/v): 1/3 ; 1/2 ; 
2/3 and 1/1 were evaluated (Table 2). 
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Water/oil ratio 1/3 1/2 2/3 1/1 
Volume (mL) Water 1 1.5 2 3 
 Oil 3 3 3 3 
NPs concentration (mg/mL) 5 10 15 25 15 
Table 2. Composition of the different formulations for the preparation of emulsions with 
Lipiodol as the oil-phase and saline as aqueous-phase. 
Emulsions were obtained by mixing through two luer lock 10 mL syringes coupled to a three-
way stop cock. During emulsification, the water phase was slowly added at a flow rate of 1 
mL/min with a syringe pump. Sixty repetitive pumping during one minute were done to 
achieve emulsification [22]. 
For doxorubicin loaded emulsions, only the 1/3 water/oil ratio was studied at a doxorubicin 
concentration of 20 mg/mL and at NP concentration of 15 mg/mL was tested. This ratio was 
selected according to published technical recommendation for conventional transarterial 
chemoembolization suggesting that the volume of drug aqueous solution should be lower than 
the volume of Lipiodol [20]. Although, a doxorubicin dissolution step was first required in the 
NP suspension, they were obtained the same way as other emulsions. Conventional 
doxorubicin emulsion was similarly prepared without NPs and without surfactant. 
2.5. Emulsion characterization 
Stability: Emulsion stability was evaluated over 24 hours at 20°C by using a Turbiscan 
Classic MA 2000 apparatus (Formulation, Toulouse, France). The apparatus uses a near-IR 
light, scans the emulsion from bottom to top and a photocell calculates the intensity of the 
transmitted and scattered light. The freshly produced emulsion was placed properly into a 
tube to avoid any perturbation of the system; the tube was not removed or even touched from 
the apparatus until the end of the measurement. Measurements were performed every 10 
minutes during the first hour, and then every hour until 24h.  
Droplet size analysis: Droplet size measurement was performed with a particle counter, shape 
and size analysis apparatus (Flowcell FC200S+HR, Occhio, Belgium). Thanks to image 
analysis, the Flowcell apparatus measures the size and the morphology of droplets. The 
emulsion was first diluted 20 times in oil. Then 0.5 mL of the diluted emulsion was passed 
through a 400 µm spacer to get a size range between 5 and 400 µm. Each sample, stored at 
20°C, was measured 5 times and at different days (D0, D7, D35). Measurements were 
performed on at least 500 droplets or more. Assuming a limited coalescence process 
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characterized by an irreversible adsorption of all the NPs at the interface, the dependence of 
the droplet diameter D with the mass mp of NPs is given by the following equation: 
 
 
 
  
            
 
 
(1) 
with C the surface coverage rate (i.e. the fraction of the droplet surface occupied by NPs),    
the particle density (for PLGA, it is 1.3 g.cm
-3
),    the particle diameter,    the volume of the 
dispersed phase [23]. 
Microscopy: All emulsions were observed with an optical microscope (Olympus B201, Japan) 
at 10x optical zoom. The images were taken 1 hour, 7 days and 35 days after the 
emulsification. Confocal microscopy was performed using a confocal scanning laser 
microscope (inverted Leica TCS SP8 – gated STED, Germany) using a HC PL APO CS2 
63x/1.40 oil immersion objective lens. The instrument was equipped with a WLL Laser (472 
nm excitation wavelength for doxorubicin and 633 nm for the reflexion mode for NPs). Red 
fluorescence emission from doxorubicin was collected with a 485-738 nm wide emission slits 
and a 592-679 nm wide emission slits for the reflexion signal under a sequential mode. 
Transmission images were acquired with the 633 nm laser line and a PMT-trans detector. The 
pinhole was set at 1.0 Airy unit. 12 bit numerical images were done with Leica SP8 LAS X 
software (Version 2.0.1; Leica, Germany).  
Freeze-fracture electron microscopy was also performed to observe our emulsions. For each 
sample, three specimen carriers (gold plated copper cupules with dome shaped indentation of 
1.4 mm central diameter) were gently filled with the corresponding formulation. The samples 
were then quickly frozen by plunge in liquid ethane with a Leica CPC apparatus (Leica 
microsystems) without cryoprotectant, and transferred in cryotubes filled with liquid nitrogen 
using the CPC chamber maintained at -160°C with gaseous nitrogen. With the Leica VCT100 
cryo preparation workstation and shuttle, samples were respectively loaded (on a holder with 
adapted retaining spring) and maintained frozen during transfers. With the Leica ACE 600 
apparatus, samples were freeze-fractured at -150°C (high vacuum around 4.10
-6
 mbar) and 
then coated by sputtering with 3 nm of iridium at 8.10
-3
 mbar and 80 mA in argon plasma). 
Finally observations were made at -150°C in a Field Emission SEM Gemini 500 (Zeiss) 
operating at 790 V, with a 15 µm objective aperture diameter and a working distance at / 
around 2.2 mm (high vacuum around 1.10
-6
 mbar in the observation chamber). Secondary 
electrons were collected with the in-lens detector. Scan speed and line or drift compensation 
integrations were adjusted during observations. 
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Viscosity: Viscosity measurements were performed with an AR-G2 rheometer (TA 
Instruments, USA), equipped with a plate-plate geometry (diameter 35 mm, gap 300 µm). 
Temperature was controlled with a Peltier plate at 20 °C. A three-step shear rate sweep was 
imposed after a 2-minute equilibration time: 1) increase of the shear rate from 1 to 10 000 s
-1
 
during 2 min (upwards curve), 2) peak hold at 10 000 s
-1
 during 30 s, 3) decrease of the shear 
rate from 10 000 s
-1
 during 2 min (downwards curve). Experiments were performed in 
triplicate for reproducibility. 
Doxorubicin release: 0.8 mL of a freshly prepared doxorubicin-loaded emulsion (equivalent 
to an amount of 4 mg of doxorubicin) was placed into GeBAflex dialyse tube with pores of 14 
kDa (GeBa, Israel). The tubes were immersed into 40 mL of 25 mM TRIS solution containing 
150 mM of NaCl (pH =7.3). Then, the whole release system was placed in an orbital shaker at 
37°C for the entire duration of the experiment. Before each aliquot withdrawing, the tubes 
were vortexed and the medium was entirely collected and replaced by fresh TRIS solution. 
For measurements, 100 µL of the release medium was collected and doxorubicin 
concentration was determined by absorption spectrometry at a wavelength of 490 nm with an 
Elisa microwell plate reader. 
Cell culture and cell viability studies: these tests were performed on two cell lines: Hep G2 (a 
human-derived carcinoma cell line widely used to evaluate toxic effects of drugs) and 
HUVEC (endothelial cells representative of the vascular endothelium). Cell culture: the 
human hepatocarcinoma Hep-G2 (ATCC HB-8065) and umbilical vein endothelial HUVEC 
(ATCC CRL-1730) cells lines were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) high glucose (4.5 g/L) supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin and incubated in humidified 
atmosphere of 5% CO2 at 37 °C. 
Cell proliferation assay: Cellular mitochondrial activity was evaluated after incubation with 
the different treatments using the 3-[4,5-dimethylthiazol-2-yl]-3,5-diphenyl tetrazolium 
bromide (MTT) test. Cells were seeded in growth medium and allowed to adhere for 24 h. 
The initial cell densities and incubation times were determined to allow the cells to remain in 
exponential growth. 
For Doxorubicin and NPs: 5000 cells were seeded in 100 µL of growth medium in 96-well 
plates (TPP), and allowed to adhere for 24 h. Cells were then treated with 100µL of 2 times 
concentrated test compounds at a series of concentrations and incubated at 37°C for 48 h.  
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For Lipiodol and emulsions: due to their viscosity, a homogenous mother solution couldn’t be 
prepared so each well of a 12 wells plate was treated individually in triplicate. 54 000 cells 
were seeded in 2000 µL of growth medium in 12-well plates (TPP), and allowed to adhere for 
24 h. Wells were then treated with the adequate volume of the product and medium was added 
to have a final volume of 2 ml. Plates were then incubated at 37°C for 48 h. 
At the end of the incubation period, MTT (Sigma–Aldrich; 5 mg.mL–1 solution in phosphate 
buffered saline; 20 μL/200 µl) was added to each well. After 1 to 4 h of incubation at 37°C, 
the culture medium was removed and replaced by DMSO (200 μL/1ml) in order to lyse the 
cells and dissolve the formazan crystals. After 5 min of stirring, the absorbance of the 
solubilized dye was measured spectrophotometrically with a microplate reader (LAB System 
Original Multiscan MS) at 570 nm. The percentage of viable cells for each treatment was 
calculated from the ratio of the absorbance of the well containing the treated cells vs. the 
average absorbance of the control wells (i.e. untreated cells). All experiments were set up in 
triplicate to determine means and standard deviations. 
2.6. Statistical analysis 
All results were mentioned as mean values  standard deviation (SD). 
3. Results 
3.1. Nanoparticles preparation and characterization 
PLGA NPs were formulated by a simple versatile nanoprecipitation process. Transmission 
Electron Microscopy showed relatively homogeneous particle sizes with spherical and smooth 
surfaces (Figure 1). The mean hydrodynamic particle diameter was found around 170 nm with 
a narrow polydispersity consistent with TEM observations. A slightly negative zeta potential 
was measured which is common for PVA coated NPs [24].  
According to contact angle analyses (Table 1), NPs were found amphiphilic, and more 
hydrophobic than hydrophilic, and consequently might favor the formation of W/O emulsion. 
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Figure 1. Transmission Electron Microscopy images of dried PLGA NPs. 
3.2. Emulsion formulation 
3.2.1. Influence of NP concentration 
The importance of solid particles concentration during formulation of Pickering emulsions 
was highlighted in previous reports [15,16]. In particular, reducing the amount of particles in 
the formulation led to the formation of very large droplets since only a small interfacial area 
can be stabilized. The influence of NP concentration on the Lipiodol emulsion formulation 
was therefore evaluated through the stability and droplet size of the resulting emulsions.  
Four different concentrations of NPs were tested: 5, 10, 15 and 25 mg/mL at a water/oil ratio 
of 1/3. All the emulsions were successfully prepared and they were all W/O emulsions. 
Microscopic aspects of the different emulsions are shown in Figure S1 in supplementary 
material. In all cases, aqueous droplets are relatively well dispersed in the continuous Lipiodol 
phase. A darker interface between the aqueous core of the droplets and Lipiodol could be 
distinguished. One could also observe that the droplets size is strongly influenced by the NP 
concentration used for each formulation. Finally, droplets were generally slightly less 
spherical when NP concentrations increased. 
To characterize the darker interface, confocal microscopy was performed using iron oxide 
containing PLGA NPs for their visualization (Figure 2a). The same global aspect was found 
compared to optical microscopy but the outlines of the droplets were highlighted by the 
presence of the NPs adsorbed at the interface. This presence was also confirmed in freeze-
fracture electron microscopy (Figure 2b). With this technique, a dense NP monolayer 
adsorbed at the droplet interface could be observed. 
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Figure 2. Images of the W/O Lipiodol Pickering emulsions at 15 mg/mL of PLGA NPs with 
a 1/3 water/oil ratio in: a) confocal microscopy (scale bar = 50 µm); b) freeze-fracture 
electron microscopy (scale bar = 5 µm). 
Immediately after formulation, evolution of the emulsion stability was followed by static light 
scattering (Turbiscan®) during 24h (curves are displayed in supplementary material Figure 
S2). As shown in Table 3 and Figure S3, whatever the NP concentration, creaming was 
rapidly observed after formulation. Creaming is the phenomenon of less dense droplets (water 
droplets in our case) rising to the top to form a dense emulsion layer, with no evolution of the 
drop size. This is a reversible phenomenon which generally occurs when droplet size is 
relatively large. There is only a gradual transition in the water droplet concentration with no 
evolution of the droplet size. A gentle manual agitation is sufficient to re-homogenize the 
emulsion with a uniform distribution of the droplets [25]. The duration and the relative height 
of the creaming both increased with the NPs concentration. For the 10, 15 and 25 mg/mL 
formulations, phase separation (in our case, droplets destabilization leading to a thin aqueous 
layer on top of the emulsion) was not observed during the time of analysis. Concerning the 5 
mg/mL emulsion, phase separation started immediately after emulsification and was stabilized 
after 2 h, causing an upper aqueous layer of a relative height of 3  0.3% compared to the 
total height of the solution. 
a) b)
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 5 mg/mL 10 mg/mL 15 mg/mL 25 mg/mL 
Creaming duration (h) 2.0  0.2 4.5  0.5 5.5  0.5 9.0  0.1 
Relative height of creaming
a
 (%) 48  2 62  1 73  1 90  1 
Relative height of phase separation
b
 (%) 3  0.3 0 0 0 
Table 3. Emulsion stability of W/O Lipiodol Pickering emulsions with different NP 
concentrations at 24h, at a water/oil ratio of 1/3. 
a)
 Height of the emulsion layer / total height,
 
b)
 Height of the top aqueous layer / total height. 
Average droplet size after emulsification (D0) decreased as the NP concentration increased, 
from 69 µm at 5 mg/mL to 24 µm at 25 mg/mL (Figure 3a). At 5 mg/mL, the diameter 
gradually increased with time (from 58 µm at D0 to 120 µm at D35) with large standard 
deviations, whereas the droplet sizes remained stable during 35 days at higher NPs 
concentrations (10, 15 and 20 mg/mL).  
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Figure 3. Droplet size of the Lipiodol Pickering emulsions a) at water/oil ratio of 1/3 with 
different NPs concentrations and b) at a fixed NPs concentration of 15 mg/mL with different 
water/oil ratios at D0, D7 and D35. 
At D35, a linear relationship between the inverse of the droplet size and the NP concentration 
could be established (r
2
 = 0.98) (Figure 4). 
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Figure 4. Inverse droplet size as a function of the NPs concentration at D35.  
3.2.2. Influence of water/oil ratio 
In addition to studying the impact of NP concentration, the effects of changing the 
water/oil ratio while keeping the rest of formulation constant was also investigated. The 
concentration of 15 mg/mL was selected to perform this study, as for this concentration, 
droplet size is more suitable for TACE [20].  
All the emulsions were successfully prepared with the desired W/O type. Microscopic 
images show similar aspects for emulsions 1/3, 1/2 and 2/3 whereas emulsion 1/1 exhibits 
more heterogeneous morphologies (supplementary material Figure S4). Indeed, presence of 
some large droplets could be observed. Inside these larger droplets, smaller droplets could be 
distinguished. This observation was confirmed by confocal microscopy (supplementary 
material Figure S5).  
All emulsions were stable without phase separation for 24 hours according analysis by 
static light scattering (supplementary material Figure S6).  
For emulsions 1/3 and 1/2, a creaming was rapidly observed after their preparation 
which stabilized after 5-6h (Table 4 and Figure S7). The relative creaming height was higher 
for emulsion 1/2 than for emulsion 1/3 (91% and 73% respectively). For the two other 
emulsions, 2/3 and 1/1, the creaming phase filled the entire system at least during the first 24 
hours. 
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 1/3 1/2 2/3 1/1 
Creaming phase duration (h) 5.5  0.5 6.0  0.5 - - 
Relative height of creaming phase (%) 73  1 91  1 100 100 
Table 4. Emulsion stability of W/O Lipiodol Pickering emulsions at a NPs concentration of 
15 mg/mL with different water/oil ratios at 24h. 
The change of the water/oil ratio did not lead to a clear effect on the average droplet 
size of the emulsions (Figure 3b). Despite a significantly higher droplet size for the emulsion 
with a water/oil ratio of 1/2, they were all in the 40-60 µm size range. After 7 and 35 days, no 
significant change was observed. 
3.2.3. Viscosity of the emulsions 
Another important characteristic of Lipiodol Pickering emulsions is their viscosity 
which is affecting their injectability through microcatheter and its ability to homogeneously 
distribute to the hepatic arteries [26]. The effect of water/oil ratio on the flow behavior of the 
Pickering emulsion was investigated at a fixed NP concentration of 15 mg/mL where the 
droplet size is optimum for the chemo-embolization (Figure 5). All emulsions behaved as a 
non-Newtonian shear-thinning fluid as the viscosity decreased with increasing shear rate 
whereas Lipiodol had a Newtonian behavior (Figure 5a). This typical shear-thinning behavior 
is attributed to the progressive ordering of the emulsion droplets at increasing shear rates [27]. 
At high shear rates, viscosities decreased down to the viscosity of Lipiodol, which could 
allow the injection of the emulsions with a reasonable force. Moreover, emulsions exhibited a 
hysteresis loop in the viscosity curves with upwards curves viscosities higher than downwards 
curves viscosities (Figure 5b), which was more remarkable as the amount of water droplets 
increased. This indicates that these emulsions demonstrated a thixotropic behavior depending 
on the water/oil ratio (the more droplets in the emulsion, the stronger the thixotropic 
behavior).  
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Figure 5. a) Viscosity vs shear rate (upwards curve) of Lipiodol Pickering emulsions at a 
fixed NP concentration of 15 mg/mL and at water/oil ratios of 1/3, 1/2, 2/3, and 1/1 ; b) 
Viscosity vs shear rate (upwards and downwards curves); for emulsions, only ratios 1/3 and 
1/1 are plotted for clarity. Upwards curves viscosities are higher than downwards curves 
viscosities. 
The presence of water droplets also significantly increased the viscosity compared to the 
viscosity of Lipiodol (Figure 5). Indeed, it can be seen from Figure 6 that the relative 
viscosity         (with   the viscosity of the emulsion and    the viscosity of the solvent, 
here Lipiodol) increased sharply as a function of the water volume fraction  . The obtained 
data are well described by the Quemada Model for hard spheres [28]:            
  , 
with    the maximum volume fraction of the water droplets. Data fitting led to         
(R=0.993), which is close to the random close packing of monodisperse hard spheres (≈ 0.64) 
[27]. Thus, water droplets interacted as hard spheres during flow, with no droplet break-up or 
deformation and no formation of droplet aggregates (which could for example trap the solvent 
and virtually increase the droplet volume fraction). 
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Figure 6. Relative viscosity vs water volume fraction for a shear rate of 5 s
-1
. Fit curve 
followed the Quemada model for dispersed systems. 
3.3. Doxorubicin loaded emulsion 
Liver TACE typically involves injection of water-soluble chemotherapies such as 
doxorubicin, epirubicin, mitomycin and cisplatin emulsified with Lipiodol. In particular, 
doxorubicin hydrochloride is recognized as the standard first-line drug for the treatment of 
HCC [20].  
To fulfil all the requirements for a suitable Lipiodol Pickering emulsion as described 
in the introduction, doxorubicin-loaded emulsion was prepared from an aqueous solution of 
doxorubicin at 20 mg/mL using a water/oil ratio of 1/3 and a NP concentration of 15 mg/mL. 
After pumping, a dark red emulsion of the desired W/O type was obtained. No specific 
difference could be observed with the unloaded emulsion prepared with saline by optical 
microscopy (Figure 7). In confocal images, the same type of morphology was also observed 
but with additional droplet red cores which correspond to the presence of doxorubicin inside 
the aqueous dispersed phase.  
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Figure 7. Doxorubicin loaded emulsion (water/oil ratio = 1/3, [NPs] = 15 mg/mL, 
[doxorubicin] = 20 mg/mL), (A) Images at D0 and D1, (B) Optical microscopy at D0 (scale 
bar = 100 µm) and (C) Confocal microscopy at D0, NPs are labelled in blue and doxorubicin 
in red (scale bar = 50 µm). 
The stability of the loaded emulsion shows similar behaviour than the unloaded 
emulsion. Rapidly, a creaming phase appeared but no phase separation was observed 
(supplementary material Figure S8). 
The doxorubicin release profile of Pickering emulsion and the control solutions are 
shown in Figure 8. After 4h of incubation in TRIS, only 5% was released from the Pickering 
emulsion compared to 60% for the conventional emulsion. After 24h, the released was 
complete for the Lipiodol emulsion while around 30% was measured for the Pickering 
emulsion. The release of doxorubicin from Pickering emulsion was significantly sustained 
compared to the one from conventional Lipiodol emulsion. 
(A)  (B) (C) 
 
D0 
 
D1 
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Figure 8. Doxorubicin release profiles from conventional Lipiodol emulsion (water/oil ratio = 
1/3, [doxorubicin] = 20 mg/mL and Pickering emulsion (water/oil ratio = 1/3, [NPs] = 15 
mg/mL, [doxorubicin] = 20 mg/mL). 
3.4. In vitro cytotoxicity studies 
3.4.1. PLGA nanoparticles 
 At low and moderate concentrations (<3 mg/mL), cell viability slightly decreases as NPs 
concentration increases for both cell types but remains above 65-70 % (Figure 9). At higher 
concentration (>3 mg/mL), cellular viability decreased down to 40% at 10 mg/mL on 
HUVEC and this effect is more pronounced on Hep G2 with a decrease down to 20 %. 
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Figure 9. Viability assays on Hep G2 and HUVEC cell lines after 48h incubation with PLGA 
NPs. Results are presented as mean  SD (n=3). 
3.4.2. Lipiodol and emulsions 
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The impact of exposure to pure Lipiodol and Pickering emulsions loaded or not with 
doxorubicin, on cell viability was monitored at different dilutions ranging from 1/1000 to 1/10 
on HUVEC and Hep G2 cell lines (Figure 10). The individual components of the empty 
emulsion induced only a moderate decrease of cell viability whatever the dilution and the cell 
lines. Besides, free doxorubicin at the same dilution led to a decrease of 90% of the cell 
viability as expected for these concentrations above IC50 (0.5 µM for Hep G2 and 4 µM for 
HUVEC, data in supplementary material). Regarding the in vitro cytotoxicity of the unloaded 
emulsion, only a minor reduction of the cell viability was noticed on HUVEC similar to the 
one of the individual components. In case of Hep G2, after 48h incubation, cell viability is 
slightly lower than the one observed on HUVEC, but remains above 70% for quite low 
dilutions as 1/50 (CNPs = 0.75 mg/mL). For doxorubicin-loaded emulsion, similar cytotoxic 
effect to free doxorubicin was observed on the two cell lines. After 48h incubation, the 
loaded-emulsion should have released almost 50% of the internalized doxorubicin 
corresponding for the highest dilution (1/1000) to a doxorubicin concentration of 40 µM 
which is far above the IC50 of doxorubicin. 
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Figure 10. Viability assays on Hep G2 and HUVEC cell lines after 48h incubation with 
PLGA NPs (nanoparticle-equivalent concentrations in brackets), Lipiodol, blank Pickering 
emulsion and doxorubicin loaded Pickering emulsion at different dilution times. For all 
dilution, cell viability of equivalent doxorubicin concentration in solution is always below 20 
% for both cell lines (data are displayed in supplementary material Figure S9). Results are 
presented as mean  SD (n=3). 
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4. Discussion 
Solid nanoparticles are noticeable alternatives to synthetic surfactants for the stabilization of 
emulsions. Thanks to their strong adsorption at the interface of two immiscible liquids, highly 
stable emulsions also called Pickering emulsions can be obtained. In many Pickering 
emulsion studies, the oils have been relatively simple in structure (hydrocarbon or silicone) 
and generally present lower density than water. These studies conclude that oil ratio and 
particle wetting properties have a strong influence on the emulsion type [29,30]. 
Lipiodol emulsion has been used for TACE procedure for over 30 years for its preferential 
tropism for the tumor compared to surrounding tissues [31]. Many studies have attempted to 
stabilize this emulsion but with limited success. This failure can be attributed to the chemical 
nature of the oil. Lipiodol is an oily mixture of iodinated poppy-seed fatty acid esters. Due to 
the presence of numerous iodine atoms, the density of Lipiodol is 1.28 g/cm
3
. The high iodine 
content combined to the high density contributes largely to difficulties encountered until now 
for the stabilisation of Lipiodol based emulsions due to physico-chemical differences with 
commonly used oils. 
Our results have demonstrated a new strategy to stabilize Lipiodol emulsion. The addition of 
PLGA NPs into the aqueous-phase of the formulation has led to inverse W/O Pickering 
emulsion by a simple emulsification process through two connected syringes. The resulting 
emulsion displayed remarkable stability against coalescence and maintained their morphology 
over several weeks thanks to the NPs which efficiently stabilize the droplets interface against 
destabilization. Their injectability could be facilitated by their shear thinning behavior at 
elevated shear rates as applied in microcatheter during injection. Moreover, the emulsion can 
be formulated in presence of high concentration of doxorubicin without affecting its 
characteristics. 
We selected PLGA NPs as emulsifier since they are used in many biomedical applications 
because of their biodegradability and biocompatibility. Few publications address emulsion 
stabilization with biodegradable NPs. Laredj-Bourezg et al demonstrated that particles of 
poly(caprolactone)-block-poly(ethylene glycol) [32] and of poly(lactic acid)-block-
poly(ethylene oxide) [33] were able to stabilize O/W emulsions using a triglyceride oil for 
topic applications. Earlier, Whitby et al have reported the use of PLGA NPs as emulsifiers 
[16]. They showed that these particles preferentially stabilise oil-in-water emulsions from a 
wide range of oils at equal volume of oil and aqueous-phase, and did not observe a phase 
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inversion at higher oil ratio. Qi et al obtained stable O/W emulsion using PLGA NPs and 
octanol as the oil phase for a large range of oil ratio, and also did not observe a phase 
inversion at high oil ratio (emulsions were unstable instead); on the contrary, the use of 
hexadecane led to an unstable emulsion [34]. In both studies, PVA was used to prepare the 
NPs, and PVA was adsorbed on the surface of the NPs, resulting in less hydrophobic NPs and 
promoting O/W emulsions. Despite this trend, in our study, highly stable Lipiodol emulsions 
were achieved over a large range of oil volume fraction and NPs concentrations. PVA was 
also used during the preparation of the NPs, but NPs hydrophobicity led to W/O emulsions for 
water/oil ratio of 1/1 or below, as desired for TACE application. As highlighted by 
microscopy analyses, the formed droplets were surrounded by PLGA NPs indicating that 
these were able to adsorb at the water/Lipiodol interface. 
At a NP concentration of 5 mg/mL, the average droplet size increased over time, indicating a 
coalescence phenomenon: the amount of NPs was not enough to cover efficiently all the 
droplets and to prevent them to coalesce and to form larger droplets. On the contrary, at 10, 
15 and 25 mg/mL, the emulsions were stable already and the droplet size did not evolve 
significantly from D0 to D35, because NPs cover efficiently droplet surface and prevent 
coalescence. Stability of an emulsion stabilized by NPs is mainly governed by a steric 
mechanism, with NPs forming a shell around the droplets, and more NPs allow to stabilize a 
larger interface, and consequently to obtain more and smaller droplets. Once the interfacial 
area is completely covered by NPs, droplets coalescence stops: this is the phenomenon of 
limited coalescence [23,35]. This process was confirmed at D35 by the linear relationship 
between the inverse of the droplet size and the NP concentration (equation (1) and Figure 4), 
indicating that the droplets reached their final size, even for NP concentration of 5 mg/mL. 
For all studied concentrations, the surface coverage rate value was comprised between 0.8 and 
0.9, corresponding to a very dense NPs monolayer packing at the water/oil interface [23], 
which seemed consistent with confocal and electron microscopy pictures (Figures 2 and 7).  
In 1995, de Baere et al have demonstrated a higher efficacy of Lipiodol emulsions when the 
aqueous droplets have a similar size as the tumor feeding arteries i.e. around 40 µm [26]. 
Therefore, the NPs concentration was set at 15 mg/ml corresponding to an average droplet 
size around 40 µm for the preparation of stable Lipiodol Pickering emulsions. 
There is a strong interest to vary the water/oil ratio for chemoembolization. Today, there is a 
consensus for the preparation of Lipiodol-drug emulsion with a water/oil ratio of 1/3 to form 
relatively stable emulsion [5]. But, for many drugs such as oxaliplatin, the amount of drug is 
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limited by the concentration of the commercially available vial. Therefore, an increase of the 
aqueous-phase ratio may allow to incorporate more chemotherapies for TACE procedure. In 
this work, the Lipiodol Pickering emulsions were stable over a large range of aqueous volume 
fraction to an equal volume of oil, providing sufficient choice for the surgeon to load desired 
concentrations of chemotherapies. 
Doxorubicin hydrochloride is an antineoplastic agent widely used in chemoembolization for 
palliative treatment of HCC. Although doxorubicin is a potent antitumor agent, its clinical 
utility is hampered by its toxicities such as cardiac damage and myelosuppression. Its delivery 
through a W/O Lipiodol emulsion system was expected to reduce/limit this toxicity. Despite a 
recent study that has shown a significant decrease of the plasmatic concentration using a 
Lipiodol emulsion prepared with contrast medium rather than saline, this system still fails to 
show a sustained release and lowering the systemic exposure [36].  
Efficient encapsulation of the anticancer drug doxorubicin into the Pickering-emulsion was 
simply performed by mixing the doxorubicin aqueous-phase containing NPs with Lipiodol. In 
spite a high doxorubicin concentration (20 mg/mL), the resulting emulsion was stable and no 
specific difference could be depicted with the unloaded emulsion of the same composition. 
The hydrophilic drug is retained in the internal phase due to its water solubility. The addition 
of PLGA NPs not only improved the stability of the emulsion but also improved considerably 
doxorubicin release. This sustained release might arise from the formation of a strong shell 
created by the NPs layer surrounding aqueous droplets which slow down the diffusion 
process. Further experiments are required to elucidate the release mechanism and investigate 
the influence of W/O ratios on the drug release. However, although NPs degradation was not 
specifically studied, it is unlikely the reason for the diffusion slowdown. Indeed, the emulsion 
was stable over a 35 day-period, with constant droplet size. In case of degradation of NPs 
during this period, droplet size is expected to change, and probably to increase, due to the 
degradation of the NP shell surrounding the droplet. This would promote destabilization 
phenomena such as coalescence which was not observed. Moreover, the doxorubicin release 
for the Pickering emulsion was very progressive over more than 10 days at 37°C (Figure 8), 
which may indicate either no degradation or a slow NP degradation under these experimental 
conditions.  
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Despite the increasing interest in Pickering technology over the last decade, very few studies 
concerning their cytotoxicity have been reported. As desired for biomedical applications, the 
Lipiodol Pickering emulsion should not release toxic sub-products or produce adverse effects 
after its injection. Therefore, in vitro tests were performed with all the components of the 
emulsion and with the entire emulsion on endothelial cells and liver cancer cells. The results 
of this investigation showed that the PLGA NPs do not induce specific toxicity until relatively 
high concentration of 3 mg/mL. This is consistent with previous findings of Grabowski et al 
that shown a similar cytotoxicity threshold on macrophages for this type of NPs [18]. 
However, a NPs concentration of 3.75 mg/mL is required to stabilize a 1/3 emulsion. In static 
cell culture environment, this NPs concentration led to a decrease of roughly 40% of the cell 
viability. It is of interest to note that transposition in much more dynamic physiological 
environment in which NPs concentration in contact with cells will be much lower and also 
subject to constant liquid replacement, would minimize the potential cytotoxicity. 
Nevertheless, additional in vivo studies will be required to evaluate the biocompatibility and 
the biodegradability of the NPs and the unloaded emulsion. To gain more information about 
the potential adverse effects of the NPs, genotoxicity assays will also be performed. 
In the investigated dilution range, both doxorubicin in solution and doxorubicin loaded 
emulsion had similar cytotoxic effect on cells. Therefore, incorporation of doxorubicin in the 
emulsion did not modify its effect against tumor cells. 
5. Conclusions 
In this work, we successfully developed a Lipiodol emulsion which remains stable over 
weeks. This emulsion answered the main requirements to allow optimum tumor uptake by 
TACE procedure: (1) stable at least 24h, (2) water-in-oil emulsion for higher tumor 
selectivity, (3) droplet sizes around 40 µm since vessels close to the tumor are between 40-60 
µm (4) loadable with a chemotherapeutic agent and ultimately (5) a sustained release of the 
chemotherapy to extend the tumor exposure. Results are very encouraging and this 
combination allows the assumption that the Lipiodol Pickering emulsion will lead to better 
efficacy and safety than the conventional emulsion. Moreover, these stable Lipiodol Pickering 
emulsions over a large range of aqueous volume fraction to an equal volume of oil, provide 
sufficient choice for the surgeon to load desired concentrations of chemotherapies. Future 
work will consist in performing in vivo studies to confirm the potential of this system to be 
used as new agent for TACE procedure. 
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